Phaseline

Companies › VelaVigo Bio

VelaVigo Bio: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VBC101–Phase 1Participants With Advanced Solid Tumor MalignanciesJul 2027
VBC103–Phase 1Participants With Advanced Solid Tumor MalignanciesDec 2027
VBC108–Phase 1Advanced Solid TumorsJul 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07136779VBC101Phase 1Participants With Advanced Solid Tumor MalignanciesOncologyJul 2027
NCT07299747VBC103Phase 1Participants With Advanced Solid Tumor MalignanciesOncologyDec 2027
NCT07700160VBC108Phase 1Advanced Solid TumorsOncologyJul 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.